loading
Schlusskurs vom Vortag:
$1.32
Offen:
$1.3
24-Stunden-Volumen:
119.85K
Relative Volume:
0.40
Marktkapitalisierung:
$56.61M
Einnahmen:
$51.13M
Nettoeinkommen (Verlust:
$-93.80M
KGV:
-0.5919
EPS:
-2.23
Netto-Cashflow:
$-129.10M
1W Leistung:
-0.75%
1M Leistung:
-3.65%
6M Leistung:
-53.02%
1J Leistung:
-60.00%
1-Tages-Spanne:
Value
$1.29
$1.34
1-Wochen-Bereich:
Value
$1.29
$1.39
52-Wochen-Spanne:
Value
$0.89
$4.29

Repare Therapeutics Inc Stock (RPTX) Company Profile

Name
Firmenname
Repare Therapeutics Inc
Name
Telefon
(857) 412-7018
Name
Adresse
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Name
Mitarbeiter
129
Name
Twitter
@reparerx
Name
Nächster Verdiensttermin
2023-08-09
Name
Neueste SEC-Einreichungen
Name
RPTX's Discussions on Twitter

Vergleichen Sie RPTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RPTX
Repare Therapeutics Inc
1.32 57.05M 51.13M -93.80M -129.10M -2.23
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-06-09 Hochstufung Stifel Hold → Buy
2023-02-03 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-01-06 Eingeleitet CapitalOne Overweight
2022-04-12 Herabstufung Stifel Buy → Hold
2022-03-17 Fortgesetzt Goldman Buy
2021-09-23 Eingeleitet Stifel Buy
2021-09-13 Eingeleitet H.C. Wainwright Buy
2021-06-28 Eingeleitet Guggenheim Buy
2021-03-01 Eingeleitet Berenberg Buy
2020-10-28 Eingeleitet Northland Capital Outperform
2020-07-14 Eingeleitet Cowen Outperform
2020-07-14 Eingeleitet Goldman Neutral
2020-07-14 Eingeleitet Morgan Stanley Overweight
2020-07-14 Eingeleitet Piper Sandler Overweight
Alle ansehen

Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten

pulisher
May 19, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) is MPM Asset Management LLC's 6th Largest Position - MarketBeat

May 19, 2025
pulisher
May 19, 2025

MPM Bioimpact LLC Sells 408,695 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat

May 19, 2025
pulisher
May 16, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World

May 16, 2025
pulisher
May 14, 2025

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News

May 14, 2025
pulisher
May 14, 2025

RPTX Advances Pipeline with Strategic Partnership | RPTX Stock N - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Tower Research Capital LLC TRC Purchases 23,127 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 14, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business - citybiz

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results - ADVFN

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Provides Business and Clinical Update and Re - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Repare Therapeutics Advances Strategic Partnerships and Clinical Trials Amid Financial Updates - TipRanks

May 13, 2025
pulisher
May 07, 2025

Repare Therapeutics Inc’s Market Journey: Closing Weak at 1.33, Down -5.00 - DWinneX

May 07, 2025
pulisher
May 07, 2025

Marshall Wace LLP Decreases Stake in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

JPMorgan Chase & Co. Boosts Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 06, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Has $455,000 Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World

May 04, 2025
pulisher
May 02, 2025

Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo

May 02, 2025
pulisher
May 01, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

May 01, 2025
pulisher
May 01, 2025

Repare Therapeutics Inc. Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News

May 01, 2025
pulisher
May 01, 2025

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace

May 01, 2025
pulisher
Apr 29, 2025

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Apr 29, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat

Apr 25, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News

Apr 25, 2025
pulisher
Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Repare Therapeutics Inc (RPTX) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Apr 23, 2025
pulisher
Apr 21, 2025

B. Riley Cuts Price Target on Repare Therapeutics to $4 From $5, Keeps Buy Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 16, 2025

Cathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare Therapeutics - Investing.com UK

Apr 16, 2025
pulisher
Apr 12, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock By Investing.com - Investing.com India

Apr 12, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood’s ARK ETF adjusts portfolio, sells Repare Therapeutics stock - Investing.com

Apr 11, 2025
pulisher
Apr 04, 2025

Repare Therapeutics Stock Hits 52-Week Low at $0.98 Amid Market Challenges - Investing.com

Apr 04, 2025
pulisher
Apr 03, 2025

Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals

Apr 03, 2025
pulisher
Apr 01, 2025

Repare Therapeutics details discovery of PLK4 inhibitor RP-1664 - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Appoints Steve Forte CEO - citybiz

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics appoints CFO as new CEO - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Announces Leadership Changes in 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Names Forte as President, CEO - MarketWatch

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Repare's New CEO Takes Helm With 3 Clinical Trial Readouts Coming in 2025 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 31, 2025

Repare Therapeutics Announces Leadership Transitions - Business Wire

Mar 31, 2025

Finanzdaten der Repare Therapeutics Inc-Aktie (RPTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):